- APC Position Statement PS-003 Biosimilar Glargine Position June 2017
- APC Position Statement PS-006 Rubefacients UPDATE Feb 2020 FINAL
- APC Position statement PS-007 Lutein Antioxidants August 2018
- APC Position statement PS-008 Tramadol-paracetamol August 2018
- APC Position statement PS-009 Dosulepin August 2018
- APC Position statement PS-010 Trimipramine August 2018
- APC Position Statement PS-013 Self Care Feb 19 FINAL
- APC Position Statement PS-019 Stoma Adhesives July 2019 FINAL
- APC Position Statement PS-020 Stoma Products July 2019 FINAL
- APC Position Statement PS-021 Liothyronine FINAL Grey Feb 2020
- APC Position Statement PS-024 Dronedarone FINAL March 2020
- APC Position Statement PS-025 Aliskiren (RED) July 2020 FINAL
- APC Position Statement PS-026 Silk Garments (GREY) July 2020 FINAL
- APC Position Statement PS-027 Methylphenidate MR Sept 2020 FINAL
- APC Postion Statement PS-014 Brand prescribing insulin Mar 2019
- APC Postion Statement PS-015 liothyronine oncology April 2019
- APC Postion Statement PS-016 liothyronine depression April 2019
- APC Postion Statement PS-017 unlicensed liothyronine April 2019
- APC Postion Statement PS-022 minocycline FINAL Feb 2020
- IMOC PS-002 Sativex MS spasticity (AMBER 3) April 22 FINAL
- IMOC PS-011 Lidocaine plasters (AMBER) FINAL - July 2022
- IMOC PS-018 Freestyle Libre 2 - April 2023
- IMOC PS-028 Methotrexate 10mg tabs (GREY) AUGUST 21 FINAL
- IMOC PS-029 DOACs August 2024
- Recommendation 005 Lisdexamfetamine ADHD children Sep 18
- Recommendation 006 Combodart
- Recommendation 007 Linaclotide in IBS Nov 2017
- Recommendation 009 Lixisenatide in combination with insulin
- Recommendation 012 Diltiazem cream for anal fissures
- Recommendation 013 Plenadren® tablets Adrenal insufficiency Sept 14
- Recommendation 014 Levonorgestrel (Jaydess®) Intrauterine device Sept 14
- Recommendation 015 Aripiprazole depot injection for schizophrenia FINAL
- Recommendation 019 Vesomni for LUTs (GREY) Oct 2017 FINAL
- Recommendation 020 Trospium overactive bladder in children FINAL
- Recommendation 021 Ulipristal pre op fibroids update Oct 2018
- Recommendation 022 Anakinra for acute gout FINAL
- Recommendation 024 Paliperidone depot schizophrenia adults (AMBER 3) – November 2023
- Recommendation 025 Lurasidone Amber2 Oct 21 FINAL
- Recommendation 026 Dapoxetine for premature ejaculation Mar 2015
- Recommendation 027 Ketotifen for food allergy Nov 17
- Recommendation 028 Nalcrom food allergy update June 2017
- Recommendation 029 SURGIFLO® for Intraoperative bleeding (Neurosurgery) Mar 2015
- Recommendation 030 Altoderm™ for mastocytosis in children April 2015
- Recommendation 031Ropinirole MR Parkinson's Disease April 2015
- Recommendation 032 Midodrine for IST and POTS (AMBER 3) Jan 18
- Recommendation 033 ivabradine for IST and POTS (AMBER 3) Jan 18
- Recommendation 034 Olopatadine in seasonal allergic conjunctivitis June 2015
- Recommendation 035 timolol eye gel for raised intraocular pressure June 2015
- Recommendation 036 Simbrinza for raised intraocular pressure June 2015
- Recommendation 037 octreotide for chylothorax August 2015
- Recommendation 038 ketamine oral solution in palliative care (RED) Oct 2015
- Recommendation 039 depot medroxyprogesterone (Sayana Press) subcut Nov 2015
- Recommendation 040 Dexamfetamine Adult ADHD (AMBER 3) - December 2022
- Recommendation 041 Lisdexamfetamine Adult ADHD (AMBER 3) - December 2022
- Recommendation 042 Alteplase for massive sub massive PE (RED) Dec 2015
- Recommendation 043 daily tadalafil for ED non-responsive to PRN Dec 2015
- Recommendation 044 Duloxetine for Stress Urinary Incontinence Dec 2015
- Recommendation 046 Methylphenidate Idiopathic hypersomnia Oct 18
- Recommendation 047 dexamfetamine Narcolepsy Oct 18
- Recommendation 048 Tiotropium Respimat in Asthma (AMBER) March 2016
- Recommendation 049 botulinum toxin hypersalivation (RED) June 2016
- Recommendation 050 Brivaracetam epilepsy (AMBER) FINAL
- Recommendation 051 Botulinum toxin in Temporomandibular jaw September 2016
- Recommendation 052 Guanfacine ADHD children (AMBER 3) Sep 2018
- Recommendation 053 Dulaglutide in Type 2 Diabetes Mellitus (AMBER 2) – June 2023
- Recommendation 054 HPV vaccine realcitrant Genital Warts (RED) FINAL November 2021
- Recommendation 055 Enstilar for psoriasis (GREEN) Aug 22 FINAL
- Recommendation 056 Ulipristal intermitent treatment fibroids (RED) Nov 19 FINAL
- Recommendation 057 botulinum toxin gastroparesis FINAL Jan 2021
- Recommendation 058 Toujeo Type 2 Diabetes update FINAL January 2021
- Recommendation 059 Insulin degludec (AMBER 2) – February 2023
- Recommendation 060 gabapentin pregabalin in RLS
- Recommendation 061 clonazepam in RLS (Amber 2) FINAL - March 2024
- Recommendation 062 Opioids in RLS (Amber 2) FINAL - March 2024
- Recommendation 063 Pitolisant for narcolepsy (RED) June 19 FINAL
- Recommendation 064 Clonidine patches for dystonia April 2017
- Recommendation 065 rivaroxaban pelvic fracture May 2017
- Recommendation 066 anti MAP therapy for IBD May 2017
- Recommendation 067 Dymista for allergic rhinitis (GREEN) July 2024
- Recommendation 068 Brimonidine gel (Mirvaso) June 2017
- Recommendation 069 Moxifloxacin eye drops June 2017
- Recommendation 070 botulinum oesophageal spasm (RED) July 2017
- Recommendation 071 botulinum toxin achalasia (RED) July 2017
- Recommendation 072 collagenase Peyronies (GREY) July 2017
- Recommendation 073 Duavive HRT (AMBER2) August 2017
- Recommendation 074 Tioguanine IBD (RED) Sept 2017
- Recommendation 075 Golimumab 100mg IBD Sept 2017
- Recommendation 076 Ferric maltol IBD (AMBER2) - February 2023
- Recommendation 077 hyperhidrosis (GREEN) October 2017
- Recommendation 078 ciclosporin eye VKC AKC children updated Dec 18
- Recommendation 079 Velphoro (RED) Nov 19 FINAL
- Recommendation 080 Oestrogen gels in menopause April 2018
- Recommendation 081 botulinum anal fissure (RED) May 2018
- Recommendation 082 Efracea (green) FINAL May 2018
- Recommendation 083 Ivermectin (green) FINAL May 2018
- Recommendation 084 Trelegy, Trimbow & Trimbow NEXThaler COPD (GREEN) June 24
- Recommendation 085 Spiriva Respimat COPD GREEN June 2018
- Recommendation 086 Spiolto COPD GREEN June 2018
- Recommendation 087 opicapone in Parkinson's Disease July 2018
- Recommendation 088 Narcolepsy cataplexy Aug 18
- Recommendation 089 Non-REM parasomnia Aug 18
- Recommendation 090 REM Behaviour Disorder (AMBER) Aug 18
- Recommendation 091 REM Behaviour Disorder (RED) Aug 18
- Recommendation 092 Levosert and Kyleena (GREEN) Oct 2024
- Recommendation 093 desmopressin (Noqdirna) FINAL Sep 2018 (RED)
- Recommendation 094 Omalizumab inducible urticaria FINAL Dec 2018
- Recommendation 095 Zyclara cream for AK (GREY) Jan 19
- Recommendation 096 Aldara cream for BCC Jan 19 (RED)
- Recommendation 097 Cariprazine (AMBER 2) FINAL July 2023
- Recommendation 098 aprepitant gastroparesis (RED) Feb 19
- Recommendation 099 lymecycline rosacea GREEN Mar 2019
- Recommendation 100 etoricoxib AS and RA (AMBER) Apr 19
- Recommendation 101 Buvidal LA injection in opioid dependence (RED) FINAL - January 2024
- Recommendation 102 Nyxoid intranasal in opioid overdose (RED) FINAL- January 2024
- Recommendation 103 Mycophenolate Sodium - AMBER 3 Sept 19 FINAL
- Recommendation 104 Rivaroxaban SVT (RED) FINAL June 2019
- Recommendation 105 testosterone gel female libido Amber 1 - May 2024 Final
- Recommendation 106 melatonin headache (RED) FINAL July 2019
- Recommendation 107 Saflutan Taptiqom PF drops AMBER2 FINAL Aug 2019
- Recommendation 108 Fixapost IOP AMBER2 FINAL Aug 2019
- Recommendation 109 Rivaroxaban HIT (RED) FINAL Oct 2019
- Recommendation 110 Glycopyrronium liquid hypersalivation AMBER 2 Sep 19 FINAL
- Recommendation 111 semaglutide Type 2 diabetes (AMBER 2) FINAL – June 2023
- Recommendation 112 Prasterone pessaries (AMBER 2) Dec 21
- Recommendation 113 Actikerall AK GREEN FINAL Feb 2020
- Recommendation 114 Imiquimod 5 percent cream AK GREEN FINAL Feb 2020
- Recommendation 115 Fiasp insulin adults (AMBER 2) FINAL update Sept 2024
- Recommendation 116 Safinamide for Parkinsons Disease (AMBER 2) July 2024
- Recommendation 117 budesonide 3mg AIH (amber 2) FINAL Nov 2020
- Recommendation 118 Slenyto paediatrics (amber 3) FINAL Nov 2020
- Recommendation 119 Botulinum toxin spasmodic dysphonia April 22 FINAL
- Recommendation 120 Invicorp erectile dysfunction (amber 2) Dec 2020 FINAL
- Recommendation 121 Vitaros erectile dysfunction (amber 2) Dec 2020 FINAL
- Recommendation 122 rivaroxaban and apixaban in LVT (Amber 2) - Final May 2024
- Recommendation 123 memantine migraine RED FINAL Jan 2021
- Recommendation 124 ORAL semaglutide Type 2 diabetes (AMBER 2) – June 2023
- Recommendation 125 Lenzetto menopause April 2021 FINAL
- Recommendation 126 Pitolisant IH (RED) FINAL Sept 22
- Recommendation 127 Dequalinium for Bacterial Vaginosis (GREEN) FINAL October 2021
- Recommendation 128 Botulinum Toxin for neuropathic pain (RED) - October 2021
- Recommendation 129 Botulinum Toxin for Hand Surgery (RED) FINAL - October 2021
- Recommendation 130 Alkindi adrenal insufficiency in paediatrics (Amber 2) - May 2024
- Recommendation 131 Xonvea for nausea and vomiting in pregnancy (AMBER 2) FINAL March 22
- Recommendation 132 Rivaroxaban VTE in Paediatrics (RED) FINAL - April 2022
- Recommendation 133 Apixaban for VTE and SSE in HD (RED) FINAL – September 2023
- Recommendation 134 Fiasp insulin (AMBER 2) Paediatrics FINAL - August 2022
- Recommendation 135 Dienogest (Amber 2) FINAL - March 2024
- Recommendation 136 Insulin degludec Paediatrics (AMBER 3) Oct 22 FINAL
- Recommendation 137 Bijuve HRT (GREEN) FINAL Oct 2022
- Recommendation 138 Pitolisant for cataplexy (RED) FINAL January 2024
- Recommendation 139 Nystatin for early voice prosthesis failure (AMBER 1) FINAL – December 2022
- Recommendation 140 Rituximab for AIHA (RED) FINAL – December 2022
- Recommendation 141 Jorveza for eosinophilic oesophagitis (AMBER 2) FINAL – March 2023
- Recommendation 142 Treatments for Co-morbid insomnia (AMBER 2) FINAL – April 2023
- Recommendation 143 Treatments for Co-morbid insomnia (RED) FINAL – April 2023
- Recommendation 144 Bisoprolol for LQTS (AMBER 2) FINAL – June 2023
- Recommendation 145 Rituximab for AIH (RED) FINAL – June 2023
- Recommendation 146 Alimemazine for dystonia in paediatrics (RED) Final – October 2023
- Recommendation 147 Colchicine for the secondary prevention of ischaemic heart disease in adults (RED) Final – November 2023
- Recommendation 148 Rivaroxaban post DVA in PAD FINAL - December 2023
- Recommendation 149 Ospemifene (Amber 2) FINAL- April 2024
- Recommendation 150 Ryaltris for allergic rhinitis (GREEN) August 2024
- Recommendation 151 Lyumjev insulin for adults (Amber 2) FINAL Sept 2024
Formulary Recommendations - current
Withdrawn and Superseded
- APC Position Statement PS-004 Interim FreeStyle Libre (withdrawn) - November 2018
- APC Position statement PS-012 FreeStyle Libre (withdrawal) July 2019
- APC recommendation 001 Lixisentide withdrawn Sept 2019
- IMOC Position statement PS-001 Biosimilar infliximab (withdrawal) Oct 2024
- IMOC PS-023 Preferred DOACs (withdrawal) August 2024
- Recommendation 002 Insulin Degludec Adults - (Withdrawn) -July 2017
- Recommendation 003 dapagliflozin type 2 diabetes (withdrawn) Nov 16
- Recommendation 004 mirabegron for OAB (withdrawn) April 2016 V1
- Recommendation 008 Dymista for allergic rhinitis (withdrawn) June 2017
- Recommendation 010 Ingenol gel (Picato) AK (withdrawn) Jan 2020
- Recommendation 011 Relvar Ellipta Astham - COPD (withdrawn) July 2016
- Recommendation 016 Golimumab in UC (withdrawn) April 2015
- Recommendation 017 Vedolizumab in Crohns disease (withdrawn) Oct 2015
- Recommendation 018 tadalafil post prostatectomy (withdrawn) May 2017
- Recommendation 023 Vedolizumab in UC (withdrawn) June 2015
- Recommendation 045 budesonide (Cortiment) - withdrawn Jan 2020
- Recommendation 066 anti-MAP for IBD (withdrawn) – February 2023
SEL IMOC homeAdult guidelines and pathwaysAnnual reports and work plansCardiovascular disease guidanceCommittee governanceCommittee minutesDiabetes guidanceFormulary recommendations and position statementsLow priority products (NHS England)Paediatric guidelines and pathwaysPolicies & general guidanceRed, Amber, Green, Grey (RAGG) list definitionsRegional Medicines Optimisation Committee (RMOC) guidanceSelf care (over the counter medicines)Shared care agreements and templatesSupporting information for primary care for significant medicines shortagesTemplate letters
